Interestingly, Taniguchi H et al. have shown that bevacizumab can concurrently reduce EphA2 and TGFBI expression in colorectal cancer, suggesting a potential synergistic function of these molecules in malignant tumors 20. Here, TGFBI is linked to colorectal cancer.